Chapter 44 : Induction of Immunological Tolerance as a Therapeutic Procedure

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Induction of Immunological Tolerance as a Therapeutic Procedure, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819194/9781555819187_Chap44-1.gif /docserver/preview/fulltext/10.1128/9781555819194/9781555819187_Chap44-2.gif


A major goal of immunosuppressive therapy in management of chronic inflammatory diseases and allogeneic transplants has been to harness long-term tolerance processes from short-term treatments. This should limit morbidity from long-term undermining of immune mechanisms, which is the hallmark of current immunosuppression.

Citation: Waldmann H, Howie D, Cobbold S. 2017. Induction of Immunological Tolerance as a Therapeutic Procedure, p 771-785. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0019-2015
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1
Figure 1

Coreceptor blockade induces transplantation tolerance and linked suppression in adult mice. CBA/Ca mice would normally rapidly reject skin grafts from either B10.BR or BALB/k mice, as they differ in minor histocompatibility antigens. If the recipients are given a brief course of nondepleting MAbs that block the CD4 and CD8 coreceptors at the time of grafting, B10.BR skin grafts are, however, permanently accepted. Remarkably, such mice made tolerant of B10.BR skin can accept third-party grafts, even from “multiple minor” different BALB/k donors, if they share sufficient antigens in common with the tolerated graft, in a process known as linked suppression. Both the induction of tolerance and the process of linked suppression are blocked by antibodies that neutralize active TGF-β.

Citation: Waldmann H, Howie D, Cobbold S. 2017. Induction of Immunological Tolerance as a Therapeutic Procedure, p 771-785. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0019-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Linked suppression depends on an interaction between regulatory T cells and antigen-presenting cells (APCs). The copresentation of tolerated (Ag1) and third-party (Ag2) antigen by the same APCs promotes an interaction between the Tregs maintaining tolerance and naive T cells that would otherwise have the potential to develop into effector cells against tissues expressing the target antigen. This “linking” of the two antigens by the APC allows the Treg to suppress the naive T cell (i.e., linked suppression) and, through the action of TGF-β (and other additional mechanisms, not shown), to also guide the naive T cell to differentiate into a second cohort of regulatory T cells, thereby further enforcing tolerance to the target antigen (i.e., infectious tolerance).

Citation: Waldmann H, Howie D, Cobbold S. 2017. Induction of Immunological Tolerance as a Therapeutic Procedure, p 771-785. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0019-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Tolerance can be induced by pharmacological modulation of DCs. Female anti-male TCR transgenic mice would normally reject male skin grafts rapidly. If such mice are administered mature (lipopolysaccharide-activated), bone marrow-derived DCs from male mice, they are further primed for graft rejection. In contrast, pretreatment of the bone marrow-derived DCs by any one of a number of modulatory agents, such as VitD3, IL-10, or TGF-β (which suppress DC maturation), induces a state of tolerance to the male antigen. Such tolerant mice now accept male skin grafts indefinitely, and while this is not associated with deletion of male-specific T cells, it does lead to the systemic induction of Foxp3 anti-male Tregs.

Citation: Waldmann H, Howie D, Cobbold S. 2017. Induction of Immunological Tolerance as a Therapeutic Procedure, p 771-785. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0019-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4
Figure 4

Regulatory T cells actively maintain tolerance within accepted skin grafts. Female anti-male TCR transgenic mice can be made tolerant of male skin grafts by a single injection of nondepleting anti-CD4 MAb. This is associated with the induction of Foxp3 Tregs, which are particularly concentrated in the tolerated skin but are often only at a low frequency systemically. This low frequency may not be sufficient to transfer tolerance with spleen cells (unless boosted by systemic antigen), but if the tolerated graft itself is adoptively transferred to empty mice, the grafts are accepted. This is not just passive acceptance by the mice that have no adaptive immune system of their own, because the administration of antibodies that block or deplete Tregs (e.g., antibodies to CD25, the hCD2. Foxp3 reporter when hCD2. Foxp3 reporter mice were the original graft recipients, or other functional blocking antibodies such as anti-CTLA4 or anti-TGF-β) all lead to rapid graft rejection. This demonstrates that Tregs are required to actively and continuously block the action of effector T cells that are also present in the grafted and tolerated skin.

Citation: Waldmann H, Howie D, Cobbold S. 2017. Induction of Immunological Tolerance as a Therapeutic Procedure, p 771-785. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0019-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 5
Figure 5

Interactions between regulatory T cells and myeloid cells maintain a tolerogenic microenvironment within tolerated tissues. Myeloid cells, including certain dendritic cells (Tol DC), type II macrophages (Mɸ), and mast cells can all express a range of enzymes, either intracellularly or secreted, that catabolize or utilize EAAs. In the context of an intact vasculature, this leads to the local depletion of amino acids, which represents one component of an immune-privileged or tolerogenic microenvironment. In addition, CD39 and CD73 coexpression on Tregs and other cell types, when enhanced by the local secretion of TGF-β, generates the anti-inflammatory mediator adenosine. Some Tregs also secrete IL-10, which further inhibits the ability of dendritic cells and Mɸ to present antigens for effector cell differentiation. Costimulatory ligands are also depleted from myeloid APCs by transendocytosis after capture by CTLA4 at the surface of Tregs. All these components of the tolerogenic microenvironment cooperate to limit the activity of naive and effector T cells while promoting Foxp3 expression and infectious tolerance. Graft rejection, on the other hand, is associated with leaking blood vessels and edema, which disrupts the tolerogenic niche, overwhelms the catabolic enzymes, and provides essential nutrients for T-cell activation and effector function.

Citation: Waldmann H, Howie D, Cobbold S. 2017. Induction of Immunological Tolerance as a Therapeutic Procedure, p 771-785. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0019-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 6
Figure 6

Nutrient and environmental sensing via mTOR regulates metabolism and Foxp3 expression. mTOR acts as an integrator of signals that arrive from a range of cell surface receptors and nutrient-sensing pathways and is critical in regulating cell metabolism and Foxp3 expression. The majority of these signals, including the TCR, growth factors, positive and negative costimulation (CD28 and PD-1), and the sphingosine 1-phosphate receptor (S1PR), converge on mTOR via the PI3K/AKT pathway, and are all dependent on recruiting phosphorylated Rheb to form the active TORC1 complex. The TORC1 complex can only be formed if there are sufficient EAAs to activate the regulator complex and the RAG proteins A to D. This means that a lack of amino acids effectively trumps all other signals via mTOR, inhibiting TORC1 activation, leading to enhanced oxidative phosphorylation (OxPhos), and allowing the Foxp3 gene to respond to TGF-β-mediated induction. Adenosine may also act indirectly on mTOR via cell surface receptors and/or adenosine transporters via AMP kinase (AMPK) signaling. It is interesting to note that at least three different classes of licensed drugs with immunomodulatory or metabolic activity (rapamycin, fingolimod, and metformin) target components of the mTOR signaling network.

Citation: Waldmann H, Howie D, Cobbold S. 2017. Induction of Immunological Tolerance as a Therapeutic Procedure, p 771-785. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0019-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 7
Figure 7

Tolerance or inflammation depends on the balance of Treg to T effector cell (Teff) and the response of mTOR to a range of microenvironmental factors. Whether the outcome of an immunological response is one of tolerance or inflammation is increasingly being considered as a balance between the number of Tregs and Teffs. This needs to be tempered by the influence of a number of other factors, particularly within the local microenvironment of the tolerated tissue, including the balance of adenosine to ATP, the effectiveness of amino acid depletion, and probably many other factors that may be associated with particular tissues and their state of health, such as inflammatory or anti-inflammatory cytokines, hypoxia, and reperfusion injury. Drugs that inhibit or activate mTOR might be able to adjust the balance point in favor of tolerance (for autoimmune disease and transplantation) or inflammation (for treatment of cancer) and provide a long-lasting therapeutic outcome from a short course of treatment.

Citation: Waldmann H, Howie D, Cobbold S. 2017. Induction of Immunological Tolerance as a Therapeutic Procedure, p 771-785. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0019-2015
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Aaltonen J,, Björses P,, Sandkuijl L,, Perheentupa J,, Peltonen L . 1994. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet 8 : 8387.[CrossRef]
2. Bennett CL,, Christie J,, Ramsdell F,, Brunkow ME,, Ferguson PJ,, Whitesell L,, Kelly TE,, Saulsbury FT,, Chance PF,, Ochs HD . 2001. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 . Nat Genet 27 : 2021.[CrossRef]
3. Wildin RS,, Ramsdell F,, Peake J,, Faravelli F,, Casanova JL,, Buist N,, Levy-Lahad E,, Mazzella M,, Goulet O,, Perroni L,, Bricarelli FD,, Byrne G,, McEuen M,, Proll S,, Appleby M,, Brunkow ME . 2001. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 27 : 1820.[CrossRef]
4. Cobbold SP,, Jayasuriya A,, Nash A,, Prospero TD,, Waldmann H . 1984. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312 : 548551.[CrossRef]
5. Benjamin RJ,, Cobbold SP,, Clark MR,, Waldmann H . 1986. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med 163 : 15391552.[CrossRef]
6. Benjamin RJ,, Waldmann H . 1986. Induction of tolerance by monoclonal antibody therapy. Nature 320 : 449451.[CrossRef]
7. Benjamin RJ,, Qin SX,, Wise MP,, Cobbold SP,, Waldmann H . 1988. Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination. Eur J Immunol 18 : 10791088.[CrossRef]
8. Qin S,, Cobbold S,, Tighe H,, Benjamin R,, Waldmann H . 1987. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol 17 : 11591165.[CrossRef]
9. Qin SX,, Wise M,, Cobbold SP,, Leong L,, Kong YC,, Parnes JR,, Waldmann H . 1990. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol 20 : 27372745.[CrossRef]
10. Waldmann H,, Qin S,, Cobbold S . 1992. Monoclonal antibodies as agents to reinduce tolerance in autoimmunity. J Autoimmun 5(Suppl A): 93102.[CrossRef]
11. Waldmann H,, Cobbold S . 1998. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol 16 : 619644.[CrossRef]
12. Qin SX,, Cobbold S,, Benjamin R,, Waldmann H . 1989. Induction of classical transplantation tolerance in the adult. J Exp Med 169 : 779794.[CrossRef]
13. Marshall SE,, Cobbold SP,, Davies JD,, Martin GM,, Phillips JM,, Waldmann H . 1996. Tolerance and suppression in a primed immune system. Transplantation 62 : 16141621.[CrossRef]
14. Daley SR,, Ma J,, Adams E,, Cobbold SP,, Waldmann H . 2007. A key role for TGF-β signaling to T cells in the long-term acceptance of allografts. J Immunol 179 : 36483654.[CrossRef]
15. Davies JD,, Leong LY,, Mellor A,, Cobbold SP,, Waldmann H . 1996. T cell suppression in transplantation tolerance through linked recognition. J Immunol 156 : 36023607.
16. Wise MP,, Bemelman F,, Cobbold SP,, Waldmann H . 1998. Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol 161 : 58135816.
17. Cobbold SP,, Qin S,, Leong LY,, Martin G,, Waldmann H . 1992. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev 129 : 165201.[CrossRef]
18. Cobbold SP,, Castejon R,, Adams E,, Zelenika D,, Graca L,, Humm S,, Waldmann H . 2004. Induction of foxP3 + regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 172 : 60036010.[CrossRef]
19. Qin S,, Cobbold SP,, Pope H,, Elliott J,, Kioussis D,, Davies J,, Waldmann H . 1993. “Infectious” transplantation tolerance. Science 259 : 974977.[CrossRef]
20. Davies JD,, Martin G,, Phillips J,, Marshall SE,, Cobbold SP,, Waldmann H . 1996. T cell regulation in adult transplantation tolerance. J Immunol 157 : 529533.
21. Scully R,, Qin S,, Cobbold S,, Waldmann H . 1994. Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells. Eur J Immunol 24 : 23832392.[CrossRef]
22. Chen Z,, Cobbold S,, Metcalfe S,, Waldmann H . 1992. Tolerance in the mouse to major histocompatibility complex-mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8. Eur J Immunol 22 : 805810.[CrossRef]
23. Waldmann H,, Cobbold S . 2001. Regulating the immune response to transplants: a role for CD4+ regulatory cells? Immunity 14 : 399406.[CrossRef]
24. Yates SF,, Paterson AM,, Nolan KF,, Cobbold SP,, Saunders NJ,, Waldmann H,, Fairchild PJ . 2007. Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J Immunol 179 : 967976.[CrossRef]
25. Farquhar CA,, Paterson AM,, Cobbold SP,, Garcia Rueda H,, Fairchild PJ,, Yates SF,, Adams E,, Saunders NJ,, Waldmann H,, Nolan KF . 2010. Tolerogenicity is not an absolute property of a dendritic cell. Eur J Immunol 40 : 17281737.[CrossRef]
26. Nolan KF,, Strong V,, Soler D,, Fairchild PJ,, Cobbold SP,, Croxton R,, Gonzalo JA,, Rubio A,, Wells M,, Waldmann H . 2004. IL-10-conditioned dendritic cells, decommissioned for recruitment of adaptive immunity, elicit innate inflammatory gene products in response to danger signals. J Immunol 172 : 22012209.[CrossRef]
27. Hawiger D,, Inaba K,, Dorsett Y,, Guo M,, Mahnke K,, Rivera M,, Ravetch JV,, Steinman RM,, Nussenzweig MC . 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194 : 769779.[CrossRef]
28. Sakaguchi S,, Sakaguchi N,, Asano M,, Itoh M,, Toda M . 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 : 11511164.
29. Powrie F,, Mason D . 1990. OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med 172 : 17011708.[CrossRef]
30. Hori S,, Nomura T,, Sakaguchi S . 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 : 10571061.[CrossRef]
31. Fontenot JD,, Gavin MA,, Rudensky AY . 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4 : 330336.[CrossRef]
32. Khattri R,, Cox T,, Yasayko SA,, Ramsdell F . 2003. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4 : 337342.[CrossRef]
33. Zelenika D,, Adams E,, Mellor A,, Simpson E,, Chandler P,, Stockinger B,, Waldmann H,, Cobbold SP . 1998. Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol 161 : 18681874.
34. Zelenika D,, Adams E,, Humm S,, Lin CY,, Waldmann H,, Cobbold SP . 2001. The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev 182 : 164179.[CrossRef]
35. Zelenika D,, Adams E,, Humm S,, Graca L,, Thompson S,, Cobbold SP,, Waldmann H . 2002. Regulatory T cells overexpress a subset of Th2 gene transcripts. J Immunol 168 : 10691079.[CrossRef]
36. Chen W,, Jin W,, Hardegen N,, Lei KJ,, Li L,, Marinos N,, McGrady G,, Wahl SM . 2003. Conversion of peripheral CD4+CD25 naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 . J Exp Med 198 : 18751886.[CrossRef]
37. Regateiro FS,, Chen Y,, Kendal AR,, Hilbrands R,, Adams E,, Cobbold SP,, Ma J,, Andersen KG,, Betz AG,, Zhang M,, Madhiwalla S,, Roberts B,, Waldmann H,, Nolan KF,, Howie D . 2012. Foxp3 expression is required for the induction of therapeutic tissue tolerance. J Immunol 189 : 39473956.[CrossRef]
38. Graca L,, Cobbold SP,, Waldmann H . 2002. Identification of regulatory T cells in tolerated allografts. J Exp Med 195 : 16411646.[CrossRef]
39. Komatsu N,, Mariotti-Ferrandiz ME,, Wang Y,, Malissen B,, Waldmann H,, Hori S . 2009. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 106 : 19031908.[CrossRef]
40. Kendal AR,, Chen Y,, Regateiro FS,, Ma J,, Adams E,, Cobbold SP,, Hori S,, Waldmann H . 2011. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med 208 : 20432053.[CrossRef]
41. Cobbold SP,, Adams E,, Graca L,, Daley S,, Yates S,, Paterson A,, Robertson NJ,, Nolan KF,, Fairchild PJ,, Waldmann H . 2006. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev 213 : 239255.[CrossRef]
42. Cobbold SP,, Adams E,, Farquhar CA,, Nolan KF,, Howie D,, Lui KO,, Fairchild PJ,, Mellor AL,, Ron D,, Waldmann H . 2009. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci USA 106 : 1205512060.[CrossRef]
43. Munn DH,, Zhou M,, Attwood JT,, Bondarev I,, Conway SJ,, Marshall B,, Brown C,, Mellor AL . 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 : 11911193.[CrossRef]
44. Munn DH,, Sharma MD,, Baban B,, Harding HP,, Zhang Y,, Ron D,, Mellor AL . 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22 : 633642.[CrossRef]
45. Kropf P,, Baud D,, Marshall SE,, Munder M,, Mosley A,, Fuentes JM,, Bangham CR,, Taylor GP,, Herath S,, Choi BS,, Soler G,, Teoh T,, Modolell M,, Müller I . 2007. Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur J Immunol 37 : 935945.[CrossRef]
46. Chabtini L,, Mfarrej B,, Mounayar M,, Zhu B,, Batal I,, Dakle PJ,, Smith BD,, Boenisch O,, Najafian N,, Akiba H,, Yagita H,, Guleria I . 2013. TIM-3 regulates innate immune cells to induce fetomaternal tolerance. J Immunol 190 : 8896.[CrossRef]
47. Stein M,, Keshav S,, Harris N,, Gordon S . 1992. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176 : 287292.[CrossRef]
48. Lumeng CN,, Bodzin JL,, Saltiel AR . 2007. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117 : 175184.[CrossRef]
49. Cobbold SP,, Adams E,, Graca L,, Waldmann H . 2003. Serial analysis of gene expression provides new insights into regulatory T cells. Semin Immunol 15 : 209214.[CrossRef]
50. Lu LF,, Lind EF,, Gondek DC,, Bennett KA,, Gleeson MW,, Pino-Lagos K,, Scott ZA,, Coyle AJ,, Reed JL,, Van Snick J,, Strom TB,, Zheng XX,, Noelle RJ . 2006. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442 : 9971002.[CrossRef]
51. Waldmann H . 2006. Immunology: protection and privilege. Nature 442 : 987988.[CrossRef]
52. Dalton DK,, Noelle RJ . 2012. The roles of mast cells in anticancer immunity. Cancer Immunol Immunother 61 : 15111520.[CrossRef]
53. Nowak EC,, de Vries VC,, Wasiuk A,, Ahonen C,, Bennett KA,, Le Mercier I,, Ha DG,, Noelle RJ . 2012. Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med 209 : 21272135.[CrossRef]
54. Cobbold SP,, Adams E,, Nolan KF,, Regateiro FS,, Waldmann H . 2010. Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link. Immunol Rev 236 : 203218.[CrossRef]
55. Loewith R,, Jacinto E,, Wullschleger S,, Lorberg A,, Crespo JL,, Bonenfant D,, Oppliger W,, Jenoe P,, Hall MN . 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10 : 457468.[CrossRef]
56. Howie D,, Waldmann H,, Cobbold S . 2014. Nutrient sensing via mTOR in T cells maintains a tolerogenic microenvironment. Front Immunol 5 : 409 10.3389/fimmu.2014.00409. [CrossRef]
57. Sancak Y,, Peterson TR,, Shaul YD,, Lindquist RA,, Thoreen CC,, Bar-Peled L,, Sabatini DM . 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320 : 14961501.[CrossRef]
58. Sancak Y,, Bar-Peled L,, Zoncu R,, Markhard AL,, Nada S,, Sabatini DM . 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141 : 290303.[CrossRef]
59. Sabatini DM,, Erdjument-Bromage H,, Lui M,, Tempst P,, Snyder SH . 1994. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78 : 3543.[CrossRef]
60. Kopf H,, de la Rosa GM,, Howard OM,, Chen X . 2007. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol 7 : 18191824.[CrossRef]
61. Charest PG,, Shen Z,, Lakoduk A,, Sasaki AT,, Briggs SP,, Firtel RA . 2010. A Ras signaling complex controls the RasC-TORC2 pathway and directed cell migration. Dev Cell 18 : 737749.[CrossRef]
62. Harada Y,, Harada Y,, Elly C,, Ying G,, Paik JH,, DePinho RA,, Liu YC . 2010. Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. J Exp Med 207 : 13811391.[CrossRef]
63. Ouyang W,, Beckett O,, Ma Q,, Paik JH,, DePinho RA,, Li MO . 2010. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol 11 : 618627.[CrossRef]
64. Zhang Q,, Cui F,, Fang L,, Hong J,, Zheng B,, Zhang JZ . 2013. TNF-α impairs differentiation and function of TGF-β-induced Treg cells in autoimmune diseases through Akt and Smad3 signaling pathway. J Mol Cell Biol 5 : 8598.[CrossRef]
65. Delgoffe GM,, Kole TP,, Zheng Y,, Zarek PE,, Matthews KL,, Xiao B,, Worley PF,, Kozma SC,, Powell JD . 2009. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30 : 832844.[CrossRef]
66. Lee K,, Gudapati P,, Dragovic S,, Spencer C,, Joyce S,, Killeen N,, Magnuson MA,, Boothby M . 2010. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32 : 743753.[CrossRef]
67. Zeng H,, Yang K,, Cloer C,, Neale G,, Vogel P,, Chi H . 2013. mTORC1 couples immune signals and metabolic programming to establish Treg-cell function. Nature 499 : 485490.[CrossRef]
68. Procaccini C,, De Rosa V,, Galgani M,, Abanni L,, Calì G,, Porcellini A,, Carbone F,, Fontana S,, Horvath TL,, La Cava A,, Matarese G . 2010. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 33 : 929941.[CrossRef]
69. Regateiro FS,, Howie D,, Nolan KF,, Agorogiannis EI,, Greaves DR,, Cobbold SP,, Waldmann H . 2011. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-β. Eur J Immunol 41 : 29552965.[CrossRef]
70. Regateiro FS,, Cobbold SP,, Waldmann H . 2013. CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol 171 : 17.[CrossRef]
71. Kobie JJ,, Shah PR,, Yang L,, Rebhahn JA,, Fowell DJ,, Mosmann TR . 2006. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J Immunol 177 : 67806786.[CrossRef]
72. Deaglio S,, Dwyer KM,, Gao W,, Friedman D,, Usheva A,, Erat A,, Chen JF,, Enjyoji K,, Linden J,, Oukka M,, Kuchroo VK,, Strom TB,, Robson SC . 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204 : 12571265.[CrossRef]
73. Ohta A,, Sitkovsky M . 2014. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol 5 : 304. doi:10.3389/fimmu.2014.00304. [CrossRef]
74. Wing K,, Onishi Y,, Prieto-Martin P,, Yamaguchi T,, Miyara M,, Fehervari Z,, Nomura T,, Sakaguchi S . 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322 : 271275.[CrossRef]
75. Mellor AL,, Chandler P,, Baban B,, Hansen AM,, Marshall B,, Pihkala J,, Waldmann H,, Cobbold S,, Adams E,, Munn DH . 2004. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 16 : 13911401.[CrossRef]
76. Qureshi OS,, Zheng Y,, Nakamura K,, Attridge K,, Manzotti C,, Schmidt EM,, Baker J,, Jeffery LE,, Kaur S,, Briggs Z,, Hou TZ,, Futter CE,, Anderson G,, Walker LS,, Sansom DM . 2011. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332 : 600603.[CrossRef]
77. Winsor-Hines D,, Merrill C,, O’Mahony M,, Rao PE,, Cobbold SP,, Waldmann H,, Ringler DJ,, Ponath PD . 2004. Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol 173 : 47154723.[CrossRef]
78. Kawai T,, Andrews D,, Colvin RB,, Sachs DH,, Cosimi AB . 2000. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6 : 114. [CrossRef]
79. Coles AJ,, Cox A,, Le Page E,, Jones J,, Trip SA,, Deans J,, Seaman S,, Miller DH,, Hale G,, Waldmann H,, Compston DA . 2006. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253 : 98108.[CrossRef]
80. Piotti G,, Ma J,, Adams E,, Cobbold S,, Waldmann H . 2014. Guiding postablative lymphocyte reconstitution as a route toward transplantation tolerance. Am J Transplant 14 : 16781689.[CrossRef]
81. Cox AL,, Thompson SA,, Jones JL,, Robertson VH,, Hale G,, Waldmann H,, Compston DA,, Coles AJ . 2005. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 35 : 33323342.[CrossRef]

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error